Aquestive Therapeutics Inc. (AQST) experienced a significant equity decline following FDA feedback indicating substantial deficiencies in the New Drug Application for Anaphylm, a sublingual film formulation designed for emergency treatment of severe allergic reactions. The regulatory agency cited unidentified deficiencies that prevent substantive discussions regarding product labeling and post-marketing surveillance requirements, effectively halting meaningful progress on the application ahead of the scheduled January 31, 2026 PDUFA action date.
The stock decline, approximately 40%, reflects investor concerns regarding the commercial viability of the candidate drug and potential impacts on the company's pipeline strategy. The FDA's identification of deficiencies without specification of remediation pathways has created uncertainty around the timeline and feasibility of achieving regulatory approval for the treatment, which targets a market segment for emergency pharmaceutical interventions.
Law firm Faruqi & Faruqi, LLP has initiated an investigation into potential shareholder claims related to the stock price depreciation. The investigation examines whether company disclosures regarding the application's status were adequate and timely, and whether shareholders were appropriately informed of regulatory risks prior to the FDA's communication.